biote Corp. (NASDAQ:BTMD - Free Report) - Equities research analysts at B. Riley upped their FY2024 earnings per share estimates for biote in a research note issued on Wednesday, November 13th. B. Riley analyst J. Van. Sinderen now forecasts that the company will post earnings per share of $0.74 for the year, up from their previous forecast of $0.50. The consensus estimate for biote's current full-year earnings is $0.53 per share. B. Riley also issued estimates for biote's Q4 2024 earnings at $0.06 EPS, FY2025 earnings at $0.47 EPS and FY2026 earnings at $0.70 EPS.
biote Price Performance
Shares of NASDAQ:BTMD traded down $1.18 during midday trading on Friday, hitting $5.39. The company had a trading volume of 484,535 shares, compared to its average volume of 165,019. biote has a twelve month low of $3.65 and a twelve month high of $8.44. The stock has a market cap of $292.25 million, a price-to-earnings ratio of 23.00 and a beta of 0.94. The business's 50-day simple moving average is $5.53 and its 200-day simple moving average is $6.28.
Institutional Investors Weigh In On biote
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC acquired a new stake in biote during the second quarter worth $42,000. The Manufacturers Life Insurance Company acquired a new stake in biote during the second quarter worth $84,000. MetLife Investment Management LLC increased its stake in biote by 129.1% during the third quarter. MetLife Investment Management LLC now owns 16,582 shares of the company's stock worth $93,000 after acquiring an additional 9,343 shares during the last quarter. Jane Street Group LLC increased its stake in biote by 24.7% during the third quarter. Jane Street Group LLC now owns 16,873 shares of the company's stock worth $94,000 after acquiring an additional 3,342 shares during the last quarter. Finally, Quarry LP acquired a new stake in biote during the third quarter worth $104,000. Institutional investors and hedge funds own 21.68% of the company's stock.
biote Company Profile
(
Get Free Report)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
See Also
Before you consider biote, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.
While biote currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
